Category: Medical device company
Industry: Drug Manufacturers - Major Quick infos Headquarters: New Brunswick, New Jersey, United States Trade prices Volume: 3.4M Market Cap: 467.1B Prev closed: Open: 166.19 High: 167.99 Low: 164.47 52 week low: 151.47 52 week high: 179.92 Dividends: Next ER: July 19, 2022 Before Market Opens
About the Company Johnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company founded in 1886.
Earnings History Date EPS / Forecast Revenue / Forecast July 19, 2022 April 19, 2022 2.67 / 2.5923.43B / 23.69BJanuary 25, 2022 2.13 / 2.1224.8B / 25.28BOctober 19, 2021 2.6 / 2.3523.34B / 23.64BJuly 21, 2021 2.48 / 2.2923.31B / 22.49BBeat! view more
Historical Data Date Price Open High Low Vol Change ER Jul 1, 2022 179.52 177.45 179.72
176.69
5.50M 1.13% Jun 30, 2022 177.51 176.86 178.29
175.03
10.69M 0.29% Jun 29, 2022 176.99 177.22 178.30
176.43
7.02M 0.03% Jun 28, 2022 176.94 182.17 182.97
176.31
9.23M -2.84% Jun 27, 2022 182.12 181.64 183.35
181.50
5.91M -0.09% Jun 24, 2022 182.29 180.78 182.53
179.98
9.30M 1.46% Jun 23, 2022 179.66 177.00 179.82
176.52
10.17M 2.23% Jun 22, 2022 175.74 172.00 177.92
171.69
10.42M 1.58% Jun 21, 2022 173.01 170.75 173.86
169.56
8.17M 2.09% Jun 17, 2022 169.46 170.63 172.20
169.24
12.49M -0.36% view more
NYSE - New York Stock Exchange
More profiles and info about the company ISIN: US4781601046 CUSIP: 478160104 Founded:January 1886 Employees:126,400 News
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020 johnsonandjohnson.gcs-web.com Jul 21, 2020 1:40 am Johnson & Johnson to Participate in Citi ‘Of Hearts and Minds’ Conference Call Series johnsonandjohnson.gcs-web.com Jul 17, 2020 11:30 pm Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa johnsonandjohnson.gcs-web.com Jul 17, 2020 9:00 pm
The Famous Fed Put Is Now a Fed Call, and the Bad News Is Piling Up barrons.com May 6, 2022 7:03 am FDA limits use of J&J COVID-19 vaccine due to risk of blood clot seekingalpha.com May 6, 2022 5:49 am COVID-19 Omicron variant is as severe as previous variants - study seekingalpha.com May 6, 2022 1:46 am J&J files suit against drug-benefit provider over use of copay assistance program - WSJ seekingalpha.com May 5, 2022 7:33 pm Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 29, 2022 11:00 pm Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 10, 2022 10:00 pm Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ESG Priorities and Progress Against Public Commitments johnsonandjohnson.gcs-web.com Jun 8, 2022 8:00 pm Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations johnsonandjohnson.gcs-web.com Jun 7, 2022 11:30 pm ETHICON LAUNCHES NEXT GENERATION ECHELON™ 3000 STAPLER DESIGNED FOR EXCEPTIONAL ACCESS AND CONTROL johnsonandjohnson.gcs-web.com Jun 7, 2022 Updated Data for Janssen’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 6, 2022 Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com Jun 5, 2022 Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma johnsonandjohnson.gcs-web.com Jun 3, 2022 10:00 pm New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years johnsonandjohnson.gcs-web.com Jun 1, 2022 10:00 pm Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA johnsonandjohnson.gcs-web.com May 31, 2022 10:00 pm European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma johnsonandjohnson.gcs-web.com May 27, 2022 Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022 johnsonandjohnson.gcs-web.com May 25, 2022 Johnson & Johnson to Provide Webcast Fireside Chat on Clinical Data to be Presented at the American Society of Clinical Oncology Annual Meeting and the Janssen Oncology Strategy and Portfolio johnsonandjohnson.gcs-web.com May 25, 2022 JNJ Dividends Ex-Dividend Amount Announced Date Record Date Payment Date May 23, 2022 1.13 Jun 7, 2022 Feb 18, 2022 1.06 Mar 8, 2022 Nov 22, 2021 1.06 Dec 7, 2021 Aug 23, 2021 1.06 Sep 7, 2021 May 24, 2021 1.06 Jun 8, 2021 view more
Key Persons Talk about Johnson below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: jnj.com Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Graham's philosophy of "value investing" has made The Intelligent Investor the stock market bible ever since its original publication in 1949.
The best book on investing ever written.
